Cognitive Effects of Oral Oxybutynin and Oxybutynin Chloride Topical Gel in Older Volunteers
Information source: Watson Pharmaceuticals
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Healthy Volunteers
Intervention: oxybutynin chloride immediate-release (Drug); oxybutynin chloride topical gel (Drug); placebo (Other)
Phase: Phase 1
Status: Completed
Sponsored by: Watson Pharmaceuticals
Summary
The purpose of this study is to explore the possible cognitive effects of oxybutynin tablets
and oxybutynin gel.
Clinical Details
Official title: Cognitive Effects of Oral Oxybutynin and Oxybutynin Chloride Topical Gel in Older Volunteers
Study design: Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary outcome: Measure of accuracy of delayed recall name-phase association test
Secondary outcome: Effects on other cognitive domains measured by various tests
Eligibility
Minimum age: 60 Years.
Maximum age: 79 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Males and females aged 60 and over
- English as a primary language
- Given written informed consent by signing and dating an informed consent form prior
to study entry
Exclusion Criteria:
- Current diseases in which the use of oxybutynin is contraindicated
- History of narrow-angle glaucoma or urinary or gastric retention
- Current use of drugs known to effect memory and cognition
Other protocol-defined inclusion/exclusion criteria may apply
Locations and Contacts
Tucson, Arizona 85741-3656, United States
National City, California 91950, United States
Maitland, Florida 32751, United States
Naples, Florida 34102, United States
Ocala, Florida 34471, United States
Atlanta, Georgia 30341-4155, United States
Additional Information
Starting date: September 2008
Last updated: September 22, 2011
|